Dr. Carlos F. Lagos began his academic career as an undergraduate student and research assistant at the Center for Genomics and Bioinformatics (CGB), Faculty of Biological Sciences at Pontificia Universidad Católica de Chile in 2005. He obtained his Pharmaceutical Chemistry degree from Pontificia Universidad Católica de Chile in 2008 working under the direction of Dr. Patricio Huenchuñir in the Design of Calpain 2 inhibitors. In 2010, he received a CONICYT scholarship for PhD studies, followed by his PhD in Biotechnology at Universidad Andres Bello (Chile) in 2016 with honors (Summa Cum Laude), under the direction of Dr. Tomas Perez-Acle and sponsorship of the National Science Award Dr. Pablo Valenzuela. The doctoral thesis focused on the Development of Calpain 2 Inhibitors, work that resulted in its first issued patent and a publication. In 2016, he was appointed Assistant Professor in the Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile. During this time, he worked on the discovery of selective inhibitors of 11beta-HSD1 and the identification of the first selective connexin hemichannels blockers. Since 2013, he joined as Assistant Professor of Pharmacochemistry at the School of Pharmacy, Faculty of Medicine and Science, Universidad San Sebastián and in 2018, Dr. Lagos moved to Universidad San Sebastian, where he founded and implemented the Chemical Biology and Drug Discovery Laboratory (CBD2). Dr. Lagos has participated in several post-graduate specialization courses in the areas of molecular modeling and simulation, drug design and high-throughput biological assays, including 2 courses held at Oxford University, with special emphasis on computational methods for drug discovery and toxicology, where he was trained by scientists from the pharmaceutical industry. He is currently Associated Professor of Pharmacochemistry at School of Pharmacy and collaborates as professor for the biomedical FCV-USS PhD programs.